Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.

Autor:	Dimas GG; 13 Dimokratias Str. Panorama, PC 55236, Thessaloniki. Greece., Didangelos TP; First Propaedeutic Medical Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki. Greece., Grekas DM; First Propaedeutic Medical Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki. Greece.
Jazyk:	angličtina
Zdroj:	Current vascular pharmacology [Curr Vasc Pharmacol] 2017; Vol. 15 (6), pp. 557-565.
DOI:	10.2174/1570161115666170202162345
Abstrakt:	Background: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs are major regulators of ECM degradation as well as structural and functional integrity in the glomerulus. In altered matrix composition diseases, glomerular damage is due to increased degradation of kidney and vessel basement membranes (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade collagen type-IV (coll-IV), which represents the key collagenous component of ECM and constitutes the architectural structure of vessels and glomerular BM. There is growing evidence implicating MMPs in atherosclerosis as well as in cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and diabetic nephropathy (DN). Conclusion: The present review discusses the role of MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model of the link between progressive glomerulosclerosis and MMP expression. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu